Stocksigma LogoStocksigma Logo

Dr Lal PathLabs to Acquire 70% Stake in SN Genelab for Up to INR 199.5 Crores

Dr Lal PathLabs approved acquiring a 70% stake in Gujarat-based genomics firm SN Genelab for an all-cash consideration of up to INR 168 Crores, plus

Dr Lal PathLabs to Acquire 70% Stake in SN Genelab for Up to INR 199.5 Crores

Dr. Lal PathLabs Ltd 路 Others (Uncategorized) 路 24 Sept 2026, 10:50 pm

Dr Lal PathLabs to Acquire 70% Stake in SN Genelab for Up to INR 199.5 Crores Dr Lal PathLabs approved acquiring a 70% stake in Gujarat-based genomics firm SN Genelab for an all-cash consideration of up to INR 168 Crores, plus performance-linked earnouts capped at INR 31.5 Crores. The target reported FY26 turnover of INR 57.96 Crores (FY25: INR 53.36 Crores; FY24: INR 43.27 Crores). The transaction expands Dr Lal PathLabs' advanced diagnostics and genomics capabilities, does not involve related-party transactions, and is slated for completion by 30th Nov'26, making SN Genelab a direct subsidiary.

Original exchange filing (PDF)

More announcements from Dr. Lal PathLabs Ltd

  • Attached 路 11 Nov 2026
  • Attached 路 10 Nov 2026
  • Attached 路 05 Nov 2026
  • Attached 路 04 Nov 2026
  • Attached 路 04 Nov 2026
  • Attached 路 04 Nov 2026
  • Dr. Lal Path Labs Ltd. has informed the Exchange regarding Appointment of Ms Vasuta Agarwal as Additional Director designated as Non- Executive Independent Director of the company w.e.f. November 04, 2026. 路 04 Nov 2026
  • Attached 路 04 Nov 2026

All Dr. Lal PathLabs Ltd announcements